Liquid Biopsy Market - Insights
A liquid biopsy is a simple and non-invasive technique that enables to discover a range of information about a tumor through a simple blood sample. Some of the commercially available liquid biopsy tests for cancer are Cologurad, Guardant360, Oncotype SEQ Liquid Select, and Target Selector liquid biopsy assays. A liquid biopsy test can detect epidermal growth factor receptor (EGFR) gene mutations, evident in non-small cell lung cancer (NSCLC). The process requires only 5 milliliters of blood and is quicker than a surgical biopsy. The blood sample is processed to get 2 milliliters of plasma that is analyzed for tumor DNA. Potential of liquid biopsies to detect disease progression or treatment resistance long before it would trigger clinical symptoms or appear on imaging scans is major factor driving growth of liquid biopsy market.
Tissue samples removed for biopsy many not show all mutations as cancer has multiple genetic mutations, whereas liquid biopsies offer an improved chance of detecting these genetic changes. Moreover, the efficiency of liquid biopsy to improve progression and survival rates in cancer is major factor driving growth of the market.
However, in December 2017, two Johns Hopkins prostate cancer researchers found differences in the results from two different liquid biopsy providers and such inconsistencies in results may hinder the growth of the market.
Rising applications of liquid biopsy owing to its advantages over conventional biopsy is expected to boost growth of the liquid biopsy market
Liquid biopsy offer efficient disease management as well as non-invasive prenatal testing (NIPT). NIPT enables diagnosis of potential risks of developing chromosomal abnormalities such as Edwards’s syndrome, Down syndrome, and X and Y chromosome abnormalities. Liquid biopsy offers complete genetic profile of the patient by providing DNA for more than one tumor. The process is non-invasive and provides no biases in results, owing to heterogeneity of the tumor tissues. The process requires small amount of sample and is cost and time effectiveness. Furthermore, applications of liquid biopsy for diagnosis of non-small cell lung cancer (NSCLC), breast cancer, coronary heart disease, prostate cancer, and others is expected to propel growth of the market. For instance, according to a new study published in Oncology Journal, in January 2018, the liquid biopsy combo involving exosomal RNA and cell-free DNA (cfDNA) improved the sensitivity of epidermal growth factor mutations in NSCLC. Furthermore, OncoCyte Corporation presented positive data from its breast cancer diagnostic test study, in December 2017, at San Antonio Breast Cancer Symposium.
The global liquid biopsy market was valued at US$ 1,824.7 million in 2016 and is expected to witness a robust CAGR of 18.3% over the forecast period (2017–2025).
Figure 1. Global Liquid Biopsy Market Share, by Application (%) 2017 and 2025
Manufacturers are focusing on development of new tests in the liquid biopsy market and this is expected to bolster growth of the liquid biopsy market over the forecast period
Established as well as small players in the liquid biopsy market are actively focusing on research and development of methods in liquid biopsy through collaborations. For instance, Biodesix—a U.S.-based company—developed a novel way of extract circulating RNA from plasma in November 2017, in collaboration with Norgen Biotek. Moreover, Precipio—a U.S.-based organization, entered into merger agreement with Transgenomic, in 2017, for commercializing ICE COLD PCR (ICP) for liquid biopsies, which preferentially enriches mutant DNA sequences over wild-type DNA through selective amplification. HaploX Biotechnology—a China-based company—raised US$ 32 Mn in financing, in January 2018, in order to integrate liquid biopsy technology, artificial intelligence, and gene sequencing.
Furthermore, in May 2017, Guardant Health, Inc. raised US$ 360 million to create cancer blood tests to deploy its test for 1 million people over the next five years. Guardant Health and MD Anderson Cancer Center launched liquid biopsy partnership, in February 2017, under which Guardant is expected to help MD Anderson to build multiple on-site liquid biopsy centers. Guardant Health announced broad, long term alliance with Pfizer Oncology to support multiple clinical programs with its Guardant360 assay, in June 2017. Moreover, Guardant Health announced that it entered into separate agreements with AstraZeneca, Merck, Merck KGaA, and Darmstadt in January 2017 to develop 500 plus gene liquid biopsy panel to speed up clinical trials and drug development. Natera collaborated with Baylor Genetics to develop a non-invasive prenatal test, Vistara, in May 2017, which aided in detecting de novo mutations in single gene disorders.
Some major players operating in the liquid biopsy market include Illumina, Inc., Roche AG, Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Qiagen N.V., Thermo Fisher Scientific Inc., Exact Sciences Corp., Biocept, Inc., Genomic Health, Inc., Guardant Health, TrovaGene Inc., CareDx Inc., Adaptive Biotechnologies Corporation, and Biocartis SA.
Liquid biopsy gained popularity among physicians owing to increasing importance of precision medicine and advantages offered by the liquid biopsy over conventional biopsy techniques. Clinical diagnosis of tumors is done by pathological testing and medical imaging in which pathological testing involves tissue biopsies, molecular pathology tests, and serological indicators tests. Among these techniques tissue biopsy is considered as a gold standard for diagnosis. However, it has certain disadvantages such as difficulty in obtaining tissues from terminal cancer patients, complications due to sampling, and result difference due to tumor heterogeneity. Liquid biopsy provides more accurate results and offers more advantages over conventional techniques. It uses circulating tumor cell detection and cell free DNA etc. techniques for early detection of the cancer.
Factors such as rising prevalence of various cancers, rising demand for minimally invasive procedures, and advantages offered by liquid biopsy over conventional tissue biopsy are supporting growth of the liquid biopsy market. Liquid biopsy offers advantages over conventional tissue biopsy such as early disease detection, real-time monitoring of the metastasis and actual treatment response, detection of primary tumors and metastasis through simple and non-invasive tests, and may be cheaper than conventional biopsy. Furthermore, prevalence of various cancers is increasing and according to National Cancer Institute, 2016, an estimated 16.8 million new cases of cancer are diagnosed in the U.S., with an around 595,690 deaths from the disease. The number of people with cancer is expected to rise to 19 million by 2024, indicating need for early disease diagnosis and treatment. Demand for minimally invasive treatments is also increasing as tissue biopsy is an invasive approach for cancer diagnosis, wherein, liquid biopsy is more convenient, which is expected to boost growth of the liquid biopsy market.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 48 market data tables and 57 figures on "Liquid Biopsy Market - Global forecast to 2025”.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.